Latest News

Amgen to stop selling Repatha at higher list price, offer low-priced option exclusively

heart, doctor, cardiac

The biotech company had kept the drug available at the higher list price in order to give payers and pharmacy benefit managers time to adjust contracts and minimize supply chain disruptions.

Source link




Related posts

Patterson Companies to Present at the 2020 J.P. Morgan Healthcare Conference

Newsemia

Medical News Today: Depression: Gene-activating drug reverses symptoms in mice

Newsemia

Shirley Family Office Sends Letter to PLx Pharma (PLXP) Board of Directors

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy